Xin Li

Title: Innovations of Inventor Xin Li

Introduction

Xin Li is a notable inventor based in Claymont, Delaware, who has made significant contributions to the field of pharmaceuticals. With a total of three patents to her name, she has focused her research on developing innovative compounds that target specific enzymes associated with cancer treatment.

Latest Patents

One of her latest patents is titled "Tricyclic heterocycles as FGFR inhibitors." This patent relates to tricyclic heterocycles and pharmaceutical compositions that act as inhibitors of the FGFR enzyme, which are useful in treating FGFR-associated diseases such as cancer. Another significant patent is "Bicyclic amines as CDK12 inhibitors." This application provides bicyclic amines that inhibit cyclin-dependent kinase 12 (CDK12), along with pharmaceutical compositions and methods for treating cancer using these compounds.

Career Highlights

Xin Li is currently employed at Incyte Corporation, where she continues to advance her research in the pharmaceutical industry. Her work has been instrumental in developing new therapeutic options for patients suffering from various forms of cancer.

Collaborations

Xin has collaborated with several colleagues, including Oleg Vechorkin and Evan Styduhar, to enhance her research efforts and drive innovation in her field.

Conclusion

Xin Li's contributions to pharmaceutical innovations, particularly in cancer treatment, highlight her role as a leading inventor in her field. Her patents reflect a commitment to advancing medical science and improving patient outcomes.